3 unknown, 2 completed, 1 not yet recruiting, 1 recruiting. 7 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 3, Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Survival: new trials by email Literature Review of Survival trials Research Report on Survival
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin - Classical Hodgkin Lymphoma, Child | Phase 2 / Phase 3 | Recruiting | Children's Cancer Group, China | 96 | 2024-09-25 | 2026-03-19 |
| Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Mitomycin, Lobaplatin - Colorectal Cancer, Chemotherapy Effect | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 201 | 2022-09-01 | 2022-02-21 |
| Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Paclitaxel, Lobaplatin - Gastric Cancer, Chemotherapy Effect | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 231 | 2021-09-18 | 2022-02-21 |
| An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC Triprilimab(JS001), Cisplatin, 5-Fluorouracil - Nasopharyngeal Carcinoma, Metastasis | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 622 | 2021-07-01 | 2021-05-18 |
| Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma MAPI chemotherapy, Apatinib Mesylate, Camrelizumab - Osteosarcoma, Survival | Phase 2 | Unknown | Peking University People's Hospital | 60 | 2020-05-01 | 2020-05-19 |
| PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer Astragalus Polysaccharides 500 mg - Cancer-related Fatigue, Survival | Phase 2 | Completed | PhytoHealth Corporation | 48 | 2019-02-19 | 2025-06-04 |
| Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients metronomic XELOX, Classic XELOX, Blood samples for pharmacological studies - Clinical Response, Toxicity | Phase 2 | Completed | National Cancer Institute, Egypt | 70 | 2016-01-01 | 2020-06-11 |
Neoplasm Metastasis (3) · Colorectal Neoplasms (2) · Drug-Related Side Effects and Adverse Reactions (1) · Esophageal Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Neoplasms (1) · Osteosarcoma (1) · Stomach Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Colonic Diseases (2) · Head and Neck Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms by Histologic Type (2) · Rectal Diseases (2)
lobaplatin (2) · Blood Specimen Collection (1) · Brentuximab Vedotin (1) · Capecitabine (1) · Cisplatin (1) · Cyclophosphamide (1) · Dacarbazine (1) · Doxorubicin (1) · Etoposide (1) · Fluorouracil (1) · Gemcitabine (1) · Injections (1) · Mitomycin (1) · Oxaliplatin (1) · Paclitaxel (1)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Children's Cancer Group, China (1) · National Cancer Institute, Egypt (1) · Peking University People's Hospital (1) · PhytoHealth Corporation (1) · Sun Yat-sen University (1)
China (4) · Taiwan (1)
Kaixiong Tao, Professor (2) · Wei Guo, M.D. (1) · Wen-Chien WC Huang, MD, PhD (1) · Yun-fei Xia, MD (1)
PMID 32306237, PMID 10091726, PMID 11813623, PMID 22287157, PMID 22831982, PMID 25680955, PMID 8156509